Heather F Warren1, Jessica L Reynolds2, John C Lipham2, Joerg Zehetner2, Nikolai A Bildzukewicz2, Paul A Taiganides3, Jody Mickley3, Ralph W Aye1, Alexander S Farivar1, Brian E Louie4. 1. Division of Thoracic Surgery, Swedish Medical Center and Cancer Institute, 1101 Madison Street Suite 900, Seattle, WA, 98104, USA. 2. Division of Upper GI and General Surgery, Keck Medical Center at University of Southern California, Los Angeles, CA, USA. 3. Knox Community Hospital, Mount Vernon, OH, USA. 4. Division of Thoracic Surgery, Swedish Medical Center and Cancer Institute, 1101 Madison Street Suite 900, Seattle, WA, 98104, USA. Brian.Louie@swedish.org.
Abstract
BACKGROUND: Magnetic sphincter augmentation (MSA) has emerged as an alternative surgical treatment of gastroesophageal reflux disease (GERD). The safety and efficacy of MSA has been previously demonstrated, although adequate comparison to Nissen fundoplication (NF) is lacking, and required to validate the role of MSA in GERD management. METHODS: A multi-institutional retrospective cohort study of patients with GERD undergoing either MSA or NF. Comparisons were made at 1 year for the overall group and for a propensity-matched group. RESULTS: A total of 415 patients (201 MSA and 214 NF) underwent surgery. The groups were similar in age, gender, and GERD-HRQL scores but significantly different in preoperative obesity (32 vs. 40 %), dysphagia (27 vs. 39 %), DeMeester scores (34 vs. 39), presence of microscopic Barrett's (18 vs. 31 %) and hiatal hernia (55 vs. 69 %). At a minimum of 1-year follow-up, 354 patients (169 MSA and 185 NF) had significant improvement in GERD-HRQL scores (pre to post: 21-3 and 19-4). MSA patients had greater ability to belch (96 vs. 69 %) and vomit (95 vs. 43 %) with less gas bloat (47 vs. 59 %). Propensity-matched cases showed similar GERD-HRQL scores and the differences in ability to belch or vomit, and gas bloat persisted in favor of MSA. Mild dysphagia was higher for MSA (44 vs. 32 %). Resumption of daily PPIs was higher for MSA (24 vs. 12, p = 0.02) with similar patient-reported satisfaction rates. CONCLUSIONS: MSA for uncomplicated GERD achieves similar improvements in quality of life and symptomatic relief, with fewer side effects, but lower PPI elimination rates when compared to propensity-matched NF cases. In appropriate candidates, MSA is a valid alternative surgical treatment for GERD management.
BACKGROUND: Magnetic sphincter augmentation (MSA) has emerged as an alternative surgical treatment of gastroesophageal reflux disease (GERD). The safety and efficacy of MSA has been previously demonstrated, although adequate comparison to Nissen fundoplication (NF) is lacking, and required to validate the role of MSA in GERD management. METHODS: A multi-institutional retrospective cohort study of patients with GERD undergoing either MSA or NF. Comparisons were made at 1 year for the overall group and for a propensity-matched group. RESULTS: A total of 415 patients (201 MSA and 214 NF) underwent surgery. The groups were similar in age, gender, and GERD-HRQL scores but significantly different in preoperative obesity (32 vs. 40 %), dysphagia (27 vs. 39 %), DeMeester scores (34 vs. 39), presence of microscopic Barrett's (18 vs. 31 %) and hiatal hernia (55 vs. 69 %). At a minimum of 1-year follow-up, 354 patients (169 MSA and 185 NF) had significant improvement in GERD-HRQL scores (pre to post: 21-3 and 19-4). MSA patients had greater ability to belch (96 vs. 69 %) and vomit (95 vs. 43 %) with less gas bloat (47 vs. 59 %). Propensity-matched cases showed similar GERD-HRQL scores and the differences in ability to belch or vomit, and gas bloat persisted in favor of MSA. Mild dysphagia was higher for MSA (44 vs. 32 %). Resumption of daily PPIs was higher for MSA (24 vs. 12, p = 0.02) with similar patient-reported satisfaction rates. CONCLUSIONS: MSA for uncomplicated GERD achieves similar improvements in quality of life and symptomatic relief, with fewer side effects, but lower PPI elimination rates when compared to propensity-matched NF cases. In appropriate candidates, MSA is a valid alternative surgical treatment for GERD management.
Authors: Jessica L Reynolds; Joerg Zehetner; Phil Wu; Shawn Shah; Nikolai Bildzukewicz; John C Lipham Journal: J Am Coll Surg Date: 2015-03-05 Impact factor: 6.113
Authors: Donald O Castell; Peter J Kahrilas; Joel E Richter; Nimish B Vakil; David A Johnson; Seth Zuckerman; Wendy Skammer; Jeffrey G Levine Journal: Am J Gastroenterol Date: 2002-03 Impact factor: 10.864
Authors: Marco Catarci; Paolo Gentileschi; Claudio Papi; Alessandro Carrara; Renato Marrese; Achille Lucio Gaspari; Giovanni Battista Grassi Journal: Ann Surg Date: 2004-03 Impact factor: 12.969
Authors: Brian E Louie; Alexander S Farivar; Dale Shultz; Christina Brennan; Eric Vallières; Ralph W Aye Journal: Ann Thorac Surg Date: 2014-06-21 Impact factor: 4.330
Authors: Jamie J Kelly; David I Watson; Kin Fah Chin; Peter G Devitt; Philip A Game; Glyn G Jamieson Journal: J Am Coll Surg Date: 2007-08-23 Impact factor: 6.113
Authors: Heather F Warren; Lisa M Brown; Matias Mihura; Alexander S Farivar; Ralph W Aye; Brian E Louie Journal: Surg Endosc Date: 2017-06-29 Impact factor: 4.584
Authors: Daniel Skubleny; Noah J Switzer; Jerry Dang; Richdeep S Gill; Xinzhe Shi; Christopher de Gara; Daniel W Birch; Clarence Wong; Matthew M Hutter; Shahzeer Karmali Journal: Surg Endosc Date: 2016-12-15 Impact factor: 4.584
Authors: Evan T Alicuben; Reginald C W Bell; Blair A Jobe; F P Buckley; C Daniel Smith; Casey J Graybeal; John C Lipham Journal: J Gastrointest Surg Date: 2018-04-17 Impact factor: 3.452
Authors: Kais A Rona; James M Tatum; Joerg Zehetner; Katrin Schwameis; Carol Chow; Kamran Samakar; Adrian Dobrowolsky; Caitlin C Houghton; Nikolai Bildzukewicz; John C Lipham Journal: Surg Endosc Date: 2018-01-16 Impact factor: 4.584